Edgar Filing: AtheroNova Inc. - Form 8-K

AtheroNova Inc. Form 8-K November 19, 2012 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: (Date of earliest event reported)

November 15, 2012

....

ATHERONOVA INC.

(Exact name of registrant as specified in charter)

Delaware

(State or other Jurisdiction of Incorporation or Organization)

000-52315 (Commission File Number) 20-1915083

(IRS Employer Identification No.)

2301 Dupont Drive, Suite

525
Irvine, CA 92612
(Address of Principal
Executive Offices and zip code)

(949) 476-1100 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: AtheroNova Inc. - Form 8-K

Item 8.01. Other Events.

On November 15, 2012, the Registrant issued a press release regarding receipt of a Notice of Issuance from the United States Patent and Trademark Office for its US Patent 8,304,383. The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits.
- 99.1 Press release entitled "AtheroNova Receives Notice of Issuance of Its US Patent 8,304,383" dated November 15, 2012.

Edgar Filing: AtheroNova Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AtheroNova Inc.

Date: November 19, 2012 By: /s/ Mark Selawski

Mark Selawski

Chief Financial Officer & Secretary